Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.61 |
| ▸ | CCR3 | P51677 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356282 | 0.85 | CCR3 (0.64) | MEN1KMT2AKDM4EALDH1A1CYP2C9 | |
| SCHEMBL3913727 | 0.84 | MAPK14 (0.65) | MEN1KMT2AALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL5366293 | 0.83 | HTT (0.67) | MEN1KMT2ACYP2C9CYP2C19MAPK14 | |
| SCHEMBL7231606 | 0.82 | CYP2C9 (0.69) | MEN1KMT2AKDM4EALDH1A1CYP2C9 | |
| SCHEMBL25237317 | 0.81 | MEN1 (0.67) | MEN1KMT2AKDM4EALDH1A1CYP2C9 | |
| SCHEMBL31178381 | 0.81 | MEN1 (0.67) | MEN1KMT2AKDM4EALDH1A1CYP2C9 | |
| SCHEMBL5359292 | 0.79 | SPR (0.60) | MEN1KMT2ACYP2C9CYP2C19MAPK14 | |
| SCHEMBL5352790 | 0.79 | CYP2C9 (0.58) | MEN1KMT2ACYP2C9CYP2C19MAPK14 | |
| SCHEMBL5353094 | 0.79 | MCHR1 (0.59) | ALDH1A1CYP2C9CYP2C19CCR3 | |
| SCHEMBL7244230 | 0.79 | MEN1 (0.69) | MEN1KMT2AALDH1A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299057-A9 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | KO SOO S | 2007-12-27 | — | — | US | claimed |
| US-7312222-B2 | Heterocyclic piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-25 | — | — | US | claimed |
| US-20040186097-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-09-23 | — | — | US | claimed |
| US-20020119980-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-29 | — | — | US | claimed |
| US-20070299057-A9 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | KO SOO S | 2007-12-27 | — | — | US | disclosed |
| US-7312222-B2 | Heterocyclic piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20040186097-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-09-23 | — | — | US | disclosed |
| US-6759411-B2 | ANTIHISTAMINES, ANTIALLERGENS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-07-06 | — | — | US | disclosed |
| US-20020119980-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-29 | — | — | US | disclosed |
| US-6331545-B1 | TREATING ASTHMA, ALLERGIC RHINITIS, ATOPIC DERMATITIS, AND INFLAMMATORY BOWEL DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-18 | — | — | US | disclosed |
| EP-1140834-A1 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035877-A1 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186097-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR4 | MEN1 4637/4885KMT2A 4132/4885KDM4E 4505/4885 |
| US-20020119980-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR4 | MEN1 4637/4885KMT2A 4132/4885KDM4E 4505/4885 |
| US-20070299057-A9 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR3, CCR1, CCR4 | MEN1 4702/4885KMT2A 4148/4885KDM4E 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.